222 related articles for article (PubMed ID: 32577400)
21. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y
J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999
[TBL] [Abstract][Full Text] [Related]
22. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
Jacobs MR; Abdelhamed AM; Good CE; Rhoads DD; Hujer KM; Hujer AM; Domitrovic TN; Rudin SD; Richter SS; van Duin D; Kreiswirth BN; Greco C; Fouts DE; Bonomo RA
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323050
[TBL] [Abstract][Full Text] [Related]
23. Disc Diffusion and ComASP
Bianco G; Boattini M; Comini S; Banche G; Cavallo R; Costa C
Antibiotics (Basel); 2023 Mar; 12(3):. PubMed ID: 36978470
[TBL] [Abstract][Full Text] [Related]
24. Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway.
Brakert L; Berneking L; Both A; Berinson B; Huang J; Aepfelbacher M; Wolschke C; Wichmann D; Rohde H
J Glob Antimicrob Resist; 2023 Sep; 34():59-62. PubMed ID: 37379881
[TBL] [Abstract][Full Text] [Related]
25. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
26. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
[TBL] [Abstract][Full Text] [Related]
27. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa.
Ito A; Nishikawa T; Matsumoto S; Yoshizawa H; Sato T; Nakamura R; Tsuji M; Yamano Y
Antimicrob Agents Chemother; 2016 Dec; 60(12):7396-7401. PubMed ID: 27736756
[TBL] [Abstract][Full Text] [Related]
28. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
Kuai J; Wang X; Wang H
Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469
[TBL] [Abstract][Full Text] [Related]
29. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.
Dobias J; Dénervaud-Tendon V; Poirel L; Nordmann P
Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2319-2327. PubMed ID: 28748397
[TBL] [Abstract][Full Text] [Related]
30. Analysis of In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Gram-Negative Bacilli by Broth Microdilution and Disk Diffusion Method: A Single-Center Study in Odisha, India.
Nayak G; Behera B; Mohanty S; Kar P; Jena J
Infect Drug Resist; 2022; 15():5887-5897. PubMed ID: 36237292
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Agar Dilution to Broth Microdilution for Testing
Albano M; Karau MJ; Schuetz AN; Patel R
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32967901
[TBL] [Abstract][Full Text] [Related]
32. Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa.
Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
Pharmacology; 2018; 101(5-6):278-284. PubMed ID: 29471305
[TBL] [Abstract][Full Text] [Related]
33. Relationship of TonB-dependent receptors with susceptibility to cefiderocol in clinical isolates of Pseudomonas aeruginosa.
Gupta A; Landman D; Quale J
J Antimicrob Chemother; 2022 Apr; 77(5):1282-1285. PubMed ID: 35134942
[TBL] [Abstract][Full Text] [Related]
34. Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
Aoki T; Yoshizawa H; Yamawaki K; Yokoo K; Sato J; Hisakawa S; Hasegawa Y; Kusano H; Sano M; Sugimoto H; Nishitani Y; Sato T; Tsuji M; Nakamura R; Nishikawa T; Yamano Y
Eur J Med Chem; 2018 Jul; 155():847-868. PubMed ID: 29960205
[TBL] [Abstract][Full Text] [Related]
35. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
36. Recurrent neurosurgical site infection by extensively drug-resistant
Bavaro DF; Romanelli F; Stolfa S; Belati A; Diella L; Ronga L; Fico C; Monno L; Mosca A; Saracino A
Infect Dis (Lond); 2021 Mar; 53(3):206-211. PubMed ID: 33295821
[TBL] [Abstract][Full Text] [Related]
37. The acquisition of transferable extrachromosomal fec operon is associated with a cefiderocol MIC increase in Enterobacterales.
Kocer K; Boutin S; Heeg K; Nurjadi D
J Antimicrob Chemother; 2022 Nov; 77(12):3487-3495. PubMed ID: 36245258
[TBL] [Abstract][Full Text] [Related]
38. An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms.
Domingues S; Lima T; Saavedra MJ; Da Silva GJ
Life (Basel); 2023 Jun; 13(7):. PubMed ID: 37511802
[TBL] [Abstract][Full Text] [Related]
39. Erratum to:
JAC Antimicrob Resist; 2021 Sep; 3(3):dlab109. PubMed ID: 34466802
[TBL] [Abstract][Full Text] [Related]
40. Erratum to:
JAC Antimicrob Resist; 2021 Sep; 3(3):dlab110. PubMed ID: 34466803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
